Profound Medical (PROF) Income Statement (2024 - 2026)
Income Statement report data from Mar 31, 2024 to Mar 31, 2026 for Profound Medical (PROF).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | |
|---|---|---|---|---|---|---|---|---|---|
Revenue and COGS | |||||||||
Total Revenue | 5.34M (-20.54%) | 6.72M (+32.81%) | 5.06M (+155.56%) | 1.98M (-15.38%) | 2.34M (-41.94%) | 4.03M (+58.66%) | 2.54M (+30.26%) | 1.95M (+59.84%) | 1.22M |
Cost Of Revenue | 1.51M (-24.12%) | 1.99M (+46.32%) | 1.36M (+130.51%) | 590K (-23.38%) | 770K (-36.36%) | 1.21M (+16.35%) | 1.04M (+28.40%) | 810K (+42.11%) | 570K |
Costof Goods And Services Sold | 1.51M (-24.12%) | 1.99M (+46.32%) | 1.36M (+130.51%) | 590K (-23.38%) | 770K (-36.36%) | 1.21M (+16.35%) | 1.04M (+28.40%) | 810K (+42.11%) | 570K |
Gross Profit | 3.83M (-4.01%) | 3.99M (+1.53%) | 3.93M (+142.59%) | 1.62M (-12.43%) | 1.85M (-37.50%) | 2.96M (+65.36%) | 1.79M (+26.06%) | 1.42M (+63.22%) | 870K |
Operating Expenses | |||||||||
Research And Development | 5.26M (+23.19%) | 4.27M (-21.22%) | 5.42M (-11.15%) | 6.10M (+26.82%) | 4.81M (+3.44%) | 4.65M (+11.51%) | 4.17M (-0.95%) | 4.21M (+6.58%) | 3.95M |
Selling General And Administrative | 6.59M (-7.05%) | 7.09M (-4.58%) | 7.43M (-20.36%) | 9.33M (+13.64%) | 8.21M (+23.27%) | 6.66M (+0.60%) | 6.62M (+30.83%) | 5.06M (+5.42%) | 4.80M |
Operating Expenses | 12M (+4.31%) | 11M (-11.53%) | 13M (-16.73%) | 15M (+18.43%) | 13M (+15.12%) | 11M (+4.82%) | 11M (+16.52%) | 9.26M (+5.95%) | 8.74M |
Depreciation And Amortization | 90K (+50.00%) | 60K (-33.33%) | 90K (-10.00%) | 100K (-16.67%) | 120K (-25.00%) | 160K (0.00%) | 160K (-11.11%) | 180K (-10.00%) | 200K |
Operating Income | |||||||||
Operating Income | -8.02M (+8.82%) | -7.37M (-17.28%) | -8.91M (-35.48%) | -13.81M (+23.63%) | -11.17M (+33.77%) | -8.35M (-7.22%) | -9.00M (+14.80%) | -7.84M (-0.51%) | -7.88M |
Ebit | -8.02M (+8.82%) | -7.37M (-17.28%) | -8.91M (-35.48%) | -13.81M (+23.63%) | -11.17M (+33.77%) | -8.35M (-7.22%) | -9.00M (+14.80%) | -7.84M (-0.51%) | -7.88M |
EBITDA | -7.93M (+8.48%) | -7.31M (-17.12%) | -8.82M (-35.62%) | -13.70M (+23.98%) | -11.05M (+35.09%) | -8.18M (-7.36%) | -8.83M (+15.27%) | -7.66M (-0.26%) | -7.68M |
Other Income / Expenses | |||||||||
Interest Expense | 80K (-72.41%) | 290K | - | - | 100K (-83.33%) | 600K | - | - | - |
Other Non Operating Income | 990K | -1.06M | 1.06M | -1.82M | 480K (-90.84%) | 5.24M | -190.00K | 940K (-29.32%) | 1.33M |
Net Income | |||||||||
Income Before Tax | -7.03M (-13.74%) | -8.15M (+3.69%) | -7.86M (-49.71%) | -15.63M (+46.35%) | -10.68M (+106.18%) | -5.18M (-43.63%) | -9.19M (+33.19%) | -6.90M (+5.50%) | -6.54M |
Income Tax Expense | 30K (0.00%) | 30K (-75.00%) | 120K (+100.00%) | 60K (+50.00%) | 40K | -240.00K | 180K (+800.00%) | 20K (-50.00%) | 40K |
Net Income From Continuing Operations | -7.05M (-13.71%) | -8.17M (+2.38%) | -7.98M (-49.14%) | -15.69M (+46.36%) | -10.72M (+116.57%) | -4.95M (-47.12%) | -9.36M (+35.26%) | -6.92M (+5.17%) | -6.58M |
Net Income | -7.05M (-13.71%) | -8.17M (+2.38%) | -7.98M (-49.14%) | -15.69M (+46.36%) | -10.72M (+116.57%) | -4.95M (-47.12%) | -9.36M (+35.26%) | -6.92M (+5.17%) | -6.58M |
Comprehensive Income Net Of Tax | -8.06M (-80.00%) | -40.29M (+358.88%) | -8.78M (-32.36%) | -12.98M (+22.22%) | -10.62M (-65.34%) | -30.64M (+248.97%) | -8.78M (+18.81%) | -7.39M (-2.12%) | -7.55M |